Key Highlights
- Capricor Therapeutics (NASDAQ:CAPR) fell 2.25% to USD 7.83 on volume of about 0.37 times its three-month average, simple arithmetic, and it appears in both the heavily shorted and small-cap growth groups with 1-year EPS growth of 48.91%.
- LENZ Therapeutics (NASDAQ:LENZ) rose 3.26% to USD 3.65, only USD 0.19 above its 52-week low of USD 3.46. Intellia Therapeutics (NASDAQ:NTLA) rose 3.73% to USD 13.07 on volume about 3.4 times average.
- Sarepta Therapeutics (NASDAQ:SRPT) fell 1.98% to USD 17.85, with 1-year EPS growth of 119.75% and a market capitalization of USD 1.923B, the largest of the four, in the October 9, 2026 session.
- No company-specific catalyst was identified for any of the four in the session, so the moves reflect published market data, and high short interest positions are the shared trait of the three names in the most shorted data.
Capricor Therapeutics (NASDAQ:CAPR): Regulatory Milestones Drive the Shares
Capricor Therapeutics (NASDAQ:CAPR) develops cell and exosome therapies, and its lead candidate, deramiocel, targets cardiomyopathy in Duchenne muscular dystrophy. Shares fell 2.25%, or USD 0.18, to USD 7.83 in the October 9, 2026 session, far below a 52-week high of USD 40.37 and above the low of USD 2.96, with a market capitalization of USD 465.693M. Volume of 2.509M shares was about 0.37 times the three-month average of 6.849M, simple arithmetic on two published numbers, so trading was quiet. The company shows 1-year EPS growth of 48.91% and appears in both the heavily shorted and small-cap growth groups, a reminder that an improving loss figure can coexist with a high short interest position. No company-specific catalyst was identified for the session. For a company with one lead product, regulatory decisions and agency communications drive the price more than quarterly results, and a single decision can move the shares sharply in either direction. Investors also watch cash and the chance of new share sales. A range this wide, from USD 2.96 to USD 40.37, shows how event driven Capricor Therapeutics (NASDAQ:CAPR) can be.
LENZ Therapeutics (NASDAQ:LENZ): A Presbyopia Drop Near Its Low
LENZ Therapeutics (NASDAQ:LENZ) is an ophthalmology company with an eye drop for presbyopia, the age-related loss of near vision. Shares rose 3.26%, or USD 0.12, to USD 3.65 in the October 9, 2026 session, only USD 0.19 above the 52-week low of USD 3.46 and far below the high of USD 49.16, with a market capitalization of USD 110.914M. Volume of 1.037M shares was about 1.25 times the three-month average of 829,742, simple arithmetic on two published numbers. No company-specific catalyst was identified, and the gain reflects published market data. A small gain near a 52-week low is a limited signal, since a stock can bounce and still sit in a long downtrend. Companies at this stage must convince eye-care professionals and patients to adopt a new product, and launch spending can be heavy before revenue builds. Cash runway and possible share sales are the main questions for LENZ Therapeutics (NASDAQ:LENZ), and rates matter because a 10-year Treasury yield near 5.25% and a Fed policy rate of 3.75% to 4.00% make outside funding costlier for small developers.
Intellia Therapeutics (NASDAQ:NTLA): Gene Editing on Heavy Volume
Intellia Therapeutics (NASDAQ:NTLA) develops in vivo CRISPR gene editing therapies, in which editing tools are delivered into the body to change a gene directly. Shares rose 3.73%, or USD 0.47, to USD 13.07 in the October 9, 2026 session, inside a 52-week range of USD 7.95 to USD 28.25 and with a market capitalization of USD 1.766B. The standout figure is volume: 13.954M shares against a three-month average of 4.158M, about 3.4 times, simple arithmetic on two published numbers. Heavy volume on a modest gain suggests larger positions changed hands, but the published data does not reveal who bought or sold. No company-specific catalyst was identified for the session, and the move reflects published market data. Gene editing carries long development timelines, safety questions and high costs, and shares often react to clinical updates and financing. As a name with a high short interest position, Intellia Therapeutics (NASDAQ:NTLA) can see exaggerated moves when short sellers cover, though that is a general mechanism and not a confirmed cause here. Readers should compare the volume spike with the price change before drawing conclusions.
Sarepta Therapeutics (NASDAQ:SRPT): Duchenne Gene Therapy at a Lower Price
Sarepta Therapeutics (NASDAQ:SRPT) sells a gene therapy for Duchenne muscular dystrophy, Elevidys, along with RNA medicines. It appears in the small-cap growth data, with 1-year EPS growth of 119.75%, and not in the most shorted data. Shares fell 1.98%, or USD 0.36, to USD 17.85 in the October 9, 2026 session, within a 52-week range of USD 14.68 to USD 24.68 and with a market capitalization of USD 1.923B. Volume of 3.504M shares was about 1.2 times the three-month average of 2.984M, simple arithmetic on two published numbers. No company-specific catalyst was identified for the session. Strong EPS growth from a low or negative base is an arithmetic effect, since a smaller loss can produce a large relative change, so the figure does not by itself show a healthy business. Gene therapy makers face safety reviews, reimbursement questions and production costs, which are the factors that can shift the shares. Sarepta Therapeutics (NASDAQ:SRPT) shares Duchenne exposure with Capricor Therapeutics, so news on one can influence sentiment on the other.
Where Things Stand
The drivers cannot be pinned down: no company-specific catalyst was identified for any of the four in the October 9, 2026 session, and each moved by less than 4%. Intellia stands out for volume about 3.4 times its average, LENZ for trading just above its 52-week low, Capricor for a very wide yearly range and Sarepta for 119.75% EPS growth. Clinical-stage developers depend on regulatory decisions, trial data and financing, and rates near 5.25% on the 10-year Treasury raise funding costs. Bank earnings begin October 13 and the CPI report arrives October 14 at 8:30 a.m. ET. None of this is a forecast.






Please wait processing your request...